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Abstract The tissue-specific expression of an antigen (P43) 
ubiquitously expressed at high levels in a variety of tumours of 
human and animal origin was investigated using a monocional 
antibody to P43. Whereas low amounts of P43 are expressed in 
the spleen, skeletal muscle and pancreas, P43 is abundantly pro- 
duced in the liver and in other tissues such as the kidney, heart 
and brain which have high levels of oxidative metabolism. Inter- 
estingiy, a related protein of higher molecular weight is abun- 
dantly expressed in the lung and in amounts which were higher 
than those observed with other tissues. The human cDNA for P43 
was isolated from a human liver cDNA library and mapped to 
chromosome 16 between p11.2 and 12 and also to a position near 
the centromere on the long arm of chromosome 17. The deduced 
amino acid sequence of P43 is remarkably similar to that of 
E. coil EF-Tu and the mitochondrial EF-Tu of S. cerevisiae with 
the structurally and functionally important amino acids of EF-Tu 
being completely conserved in P43. A comparison of the distri- 
bution of P43 and a mitochondrial protein Hsp 60 among differ- 
ent cellular fractions indicated a fikely mitochondrial localisation 
for P43. Taken together these results suggest hat P43 is a human 
mitochondrial elongation factor. 
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1. Introduction 
The aberrant expression of many important regulatory pro- 
teins is observed in tumour cells and the identification and 
study of the genes of  these products has greatly increased our 
understanding of regulatory processes in normal and malignant 
cells. One novel approach taken to identify such proteins in- 
volved the screening of monoclonal antibodies raised against 
total human hepatoma cell proteins for antibodies which de- 
tected tumour specific antigens. This work led to identification 
of an antigen (P43) which was ubiquitously expressed at high 
levels in a variety of tumours derived from humans and other 
animals [1]. The protein sequence of three tryptic peptides of 
P43 revealed 50-70% homology to different domains of  the 
eukaryotic-elongation factor EF-1 a and also to the prokaryotic 
factor EF-Tu suggesting that P43 might be a member of the 
GTPase superfamily of proteins which carry out diverse cell 
functions. 
We have now investigated the expression levels of P43 in 
different issues and describe the isolation and characterisation 
of the cDNA for P43. The evidence presented suggests that P43 
may be a human mitochondrial elongation factor. 
*Corresponding author. 
2. Materials and methods 
2.1. Preparation of cell and mitochondrial protein extracts 
Cultured cells and mouse tissues were harvested in PBS containing 
10 mM EDTA and lysed by dounce homogenisation in RIPA buffer 
(0.1% SDS, 1% sodium deoxycholate, 1% NP40, 10 mM NaHPO4, 10 
mM EDTA, pH 7.5) to which a mixture of protease inhibitors was 
added at the following concentrations (0.2 mM PMSF, 1.5/.tg/ml apro- 
tinin, 0.5 mg/ml eupeptin 1mg/ml pepstatin, and 0.5/lg/ml E-64). The 
viscous lysates were then sonicated for 20 s and centrifuged to remove 
the cellular debris and the cleared extracts tored at -20°C. Mitochon- 
dria were isolated from HeLa cells by gentle homogenisation i  10 
volumes of homogenisation buffer (50 mM sucrose, 200 mM sorbitol, 
1 mM EDTA, 5 mM Tris-HCl, pH 7.5) in a dounce homogeniser. 
Unlysed cells and nuclei were removed by two successive centifugation 
steps at 1,000 x g for 10 rain. The mitochondria were then recovered 
from the supernatant by centifugation at 10,000 x g for 20 min and 
washed three times in homogenisation buffer. Crude mitochondrial 
protein extracts were prepared by lysing the mitochondrial pellets in 
homogenisation buffer containing 0.5% NP-40. Proportional amounts 
of the mitochondrial protein extracts and supernatant fractions from 
the isolation and washing steps were mixed with 2 x SDS-PAGE sam- 
ple buffer [2] and boiled for 10 min before lectrophoresis in denaturing 
polyacrylamide g ls. 
2.2. lmmunoblotting 
Proteins were separated by electrophoresis in 12.5% SDS poly- 
acrylamide gels and electroblotted onto nitrocellulose [3]. The transfer 
of protein was checked by reversibly staining the filter with Ponceau 
S, after which P43 was detected by the use of an affinity purified 
monoclonal ntibody (MAb 68), horse-radish peroxidase (HRP) conju- 
gated rabbit anti-mouse immunoglobulins and the Amersham en- 
hanced chemiluminescence (ECL) detection system. 
2.3. Construction fthe cDNA expression library 
Total cellular RNA was prepared from cells of the human hepatoma 
cell line PLC/PRF/5 (ECACC 85061113) harvested from ten culture 
dishes (10 cm diameter) at 50% confluence using the single step extrac- 
tion method of Chomozynski and Sacchi [4]. Poly(A) ÷ RNA was 
isolated from purified total RNA using pre-packed spun columns con- 
taining oligo(dT)-cellulose (Pharmacia LKB) according to the manu- 
facturers recommendations. Purified RNAs were analysed by electro- 
phoresis in agarose gels containing 2% formaldehyde [5]. A cDNA 
library was prepared from 5 ~tg of purified poly(A) ÷ RNA using a 
lambda ZAP-cDNA synthesis kit and packaged invitro using Gigapack 
II gold packaging extract (Stratagene Ltd). Each 100 ng of packaged 
cDNA yielded approximately 3 × 106 recombinant bacteriophages. 
2.4. Screening of the cDNA library 
In order to design oligonucleotide probes for screening the cDNA 
library the p43 protein was purified by affinity chromatography using 
the monoclonal ntibody and three peptide amino acid sequences par- 
tially determined [1]. Based on the longest peptide sequence two long 
(54 nt) 'guessmer' oligonucleotides ( ense and antisense) were syn- 
thesised by taking into consideration the frequency of codon usage in 
human genes [6]. The oligonucleotides (which overlapped by 18 nt at 
their 3' ends) were annealed together and radiolabeled by incubation 
with Klenow enzyme in the presence 32p-radiolabeled dCTP and dATP 
and unlabelled GTP and dTTP using standard conditions [5]. A sec- 
ond probe based on a shorter peptide sequence was synthesised as a 
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mixture of oligonucleotides reflecting all codon combinations and in- 
corporated a 20 nt long T-tail for radiolabelling with [~-32p]dATP by 
the hairpin extension method [7]. About 6 x 105 recombinant plaques 
were screened by plaque hybridisation as described [8,9]. Hybridised 
filters were washed at 42°C in 0.2 x SSC (1 x SSC = 0.15 M NaCI, 15 
mM sodium citrate) containing 0.1% SDS and exposed to X-ray film 
for 2 3 days at -70°C using intensifying screens. Forty positive plaques 
were identified from duplicate filters and twenty of these plaque puri- 
fied by standard procedures [5]. 
2.5. Subcloning and DNA sequencing 
Plasmid Bluescript containing the cDNA inserts were obtained by in 
vivo excision and recircularisation f phagemid DNA from the lambda 
ZAP according to the procedure recommended by the manufacturer 
(Stratagene Ltd). Restriction endonuclease mapping of the cDNA in- 
serts and the subcloning of DNA fragments for sequencing was per- 
formed using standard procedures [5]. Denatured plasmid DNA was 
sequenced by the dideoxy chain-termination method of Sanger et al. 
[10] using commercially available kits. The restriction endonuclease 
map and sequencing strategy for P43 are shown below. The coding 
region is indicated by an open bar and arrows indicate the extent and 
direction of the sequence determination. A database of the eDNA 
sequence was compiled using the Staden software package [11]. Com- 
parisons with known nucleic and amino acid sequences were carried out 
using sequence analysis programs for the VAX [12]. 
2.6. Transfection a d expression of P#3 in Chang liver cells 
Cultured Chang liver cells (line CCL-13) were transfected with 15 ,ug 
of plasmid pCMVP43 containing the full-length cDNA for P43 down- 
stream of the CMV promoter using the standard calcium phosphate 
procedure [13]. A duplicate series of transfections with plasmid pCH 110 
(Pharmacia) expressing fl-galactosidase indicated that 5-10% of the 
cells had taken up plasmid DNA. Total protein extracts were prepared 
from cells 48 h after transfection and assayed for P43 expression by 
immunoblotting with MAb68 as described above. 
2.7. Southern and Northern analysis 
Purified genomic DNA (10/lg/track) was digested with restriction 
enzymes using the conditions recommended by the manufacturer and 
separated by agarose gel electrophoresis [5]. Phage lambda DNA di- 
gested with HindIII were included as molecular size markers. The DNA 
fragments were transferred to nitrocellulose filters by the method of 
Southern [14]. Northern blots of cellular mRNA were prepared by 
standard procedures [5]. Filters were hybridised at 42°C with a ran- 
domly primed [32p]dCTP labelled probe in 5 x SSC containing 50% 
formamide, 10% dextran sulphate, 5x Denhardts olution and 0.05% 
sodium pyrophosphate. The filters were washed in 0.2 x SSC, 0.1% 
SDS at 65°C and autoradiographed at -70°C for 1-2 days with the use 
of intensifying screens. 
2.8. Fluorescence in situ hybridisation 
Whole plasmid DNA was biotinylated by nick translation [15]. Met- 
aphase chromosome spreads were prepared from a normal human male 
lymphoblastoid cell line following a standard methotrexate block and 
BrdU release protocol. Fluorescence in situ hybridisation was per- 
formed essentially as described by Fan et al. [16] except hat proteinase 
K digestion was carried out prior to denaturation i 70% formamide 
in 2 x SSC at 65°C for 2 rain. Forty nanograms of biotinylated probe 
and 5 ~g of sonicated placental DNA were mixed with 15/11 of hy- 
bridisation buffer and denatured at 65°C for 10 min and applied to 
prewarmed slides for hybridisation overnight at 42°C. The biotinylated 
probe was detected by incubation with avidin-FITC (4gtg/ml in 5% non 
fat milk, 0.05% Tween 20, 4 x SSC), and the signal amplified by succes- 
sive incubations with biotinylated anti-avidin antibody and avidin 
FITC respectively [17]. The slides were finally mounted in antifade 
(Citifluor AF1) containing a mixture of propidium iodide and DAPI 
[16] and analysed using a Nikon epifluorescence microscope and MRC 
Lasersharp 600 confocal imaging system (Bio-Rad). 
3. Results 
3.1. DifJerential expression of P43 in normal tissues 
The monoclonal antibody MAb68, raised to human P43, 
detects a protein of the same size in woodchuck, mouse and fish 
(Xiphophorus) cells suggesting that the antigen is highly con- 
served. We have used MAb68 to compare the relative amounts 
of P43 antigen in total cell protein extracts from different 
mouse tissues. Western blots of approximately equal amounts 
of total cell proteins isolated from different mouse tissues show 
that while relatively low amounts of P43 are expressed in the 
spleen, muscle and pancreas, P43 is abundantly produced in the 
liver, kidney, heart and brain tissue (Fig. 1). Most striking was 
the detection of a protein of apparently higher molecular weight 
(50 kDa) which was highly expressed in the lung and also 
detected in trace amounts in the liver and kidney (Fig. 1). 
Relatively low amounts of the 43 kDa antigen were also de- 
tected in protein extracts from lung tissue. To check that the 
results observed were not due to differences in the amounts of 
protein loaded, which might be caused by the high level expres- 
sion of certain tissue-specific proteins, identical protein gels 
were also analysed by Coomassie blue staining (data not 
shown). Similar results were obtained using tissues from 6 indi- 
vidual animals indicating that the pattern of tissue expression 
shown in Fig. 1 is reproducible and representative. 
3.2. Isolation and nucleotide sequence analysis of the cDNA for 
p43 
A lambda ZAP bacteriophage cDNA library of the human 
hepatoma cell line PLC/PRF/5 was screened with oligonucleo- 
tide probes based on the amino acid sequences derived from 
three peptide fragments of affinity purified P43 as described in 
section 2. Forty positive clones were identified from about 
6 x 105 plaques and 10 of these were isolated for further analy- 
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Fig. 1. (A) Western blot analysis of the P43 expression in different 
mouse tissues. Approximately equal amounts of total cell protein were 
loaded in each track as follows; L, liver; K, kidney; Lg, lung; S, spleen; 
M, muscle (gastrocnemus); H, heart; B, brain; P, pancreas. Protein 
extracts from the human HeLa cell line were loaded in track labelled 
P43. Proteins recovered at different stages during the isolation of mito- 
chondria from intact HeLa cells were analysed by immunoblotting 
using (B) the monoclonal antibody to P43 and (C) antisera to Hsp 60. 
The final volume of each fraction was kept constant and equal volumes 
were loaded in each track in order to analyse the relative proportion 
of P43 and Hsp 60 in the different fractions. Tracks: 1, unlysed cells and 
nuclei; 2, first wash of nuclear pellet; 3, second wash of nuclear pellet; 
4, mitochondria fraction; 5, first wash of the mitochondria; 6, second 
wash of mitochondria; 7, cytoplasmic fraction. 
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Fig. 2. Expression of P43 in Chang liver cells (CCL- 13). (A) Coomassie 
brilliant blue stained gel of total protein extracts howing that similar 
amounts of protein were loaded in tracks 1 and 2. (B) Western blot 
analysis of P43 expression. Tracks: 1, protein extract from untrans- 
fected cells; 2, protein extract from cells transfected with pCMVP43. 
sis. The sequencing of the ends of these cDNAs revealed that 
they were of all homologous and clone pBS43.5, having one of 
the longest cDNA inserts, was completely sequenced. Cultures 
of clone pBS43.5 produced acDNA fusion protein upon induc- 
tion with IPTG which was specifically detected by MAb68 
(data not shown). 
In order to obtain further evidence that the cDNA we have 
isolated encodes the P43 gene Chang liver cells (line CCL 13) 
were transfected with 15/lg of a plasmid expressing the full- 
length cDNA under control of the CMV promoter. Im- 
munoblotting with the monoclonal antibody MAb68 showed 
that the expression of P43 was substantially increased in trans- 
fected cells (Fig. 2). 
Analysis of the complete nucleotide sequence of the cloned 
cDNA revealed one long open reading frame (ORF) encoding 
the three tryptic peptide fragments of P43 which had been 
previously sequenced (Fig. 3). No start codon could be found 
in clone pBS43.5 but by aligning the overlapping N-terminal 
sequences of a second clone pBS43.7, with that of pBS43.5 it 
was possible to identify two putative start codons (only 6 nt 
apart and in the same reading frame) which would initiate 
translation of the longest ORF. As N-terminal sequence analy- 
sis of the protein was not possible it is not known which of these 
two closely spaced start codons is used to initiate translation 
of P43. For the purposes of this paper we have used the longest 
predicted ORF for analysis of the nucleotide and amino acids 
sequences of P43. This open reading frame of 1356 nt would 
code for a polypeptide of 452 amino acids with a predicted 
molecular weight of 49.5 kDa. 
3.3. The predicted amino acid sequence of the P43 protein 
A computer assisted comparison of the deduced amino acid 
sequence of P43 with that of proteins available in the database 
revealed a striking homology to the translation elongation fac- 
tors found in bacteria nd eukaryotic mitochondria. The pro- 
tein sequences of P43, the S. eerevisiae mitochondrial elonga- 
tion factor mEF-Tu and E. coli EF-Tu are compared in Fig. 3. 
While the first 43 amino acids of the yeast mEF-Tu share little 
homology with EF-Tu of E. coli the remaining protein sequence 
is identical at 62.2% of residues. The extended N-terminal 
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sequence of the yeast EFTu has been attributed to the presence 
of a N-terminal signal sequence required for translocation of 
the protein into the yeast mitochondria. Similarly, the first 
region of homology between P43 and EF-Tu of E. coli begins 
at the arginine residues at positions 56 and 7 respectively. The 
E. coli EF-Tu sequence is identical to P43 at 54.3% of positions 
with a high proportion of the other corresponding residues 
having similar biochemical properties (Fig. 4). A computer 
assisted alignment of the yeast mEF-Tu and P43 amino acid 
sequences revealed that 56.1% of the yeast residues were iden- 
tical to P43 and that most of the remaining amino acids were 
conserved with respect to their biochemical properties (Fig. 4). 
Although the N-terminal amino acid sequences of P43 and 
yeast mEF-tu are less well conserved than other regions of the 
proteins they display similar features. Both N-terminal se- 
quences encode predominantly hydrophobic amino acids and 
a moderate number of positively charged lysine and arginine 
residues but no negatively charged amino acids (Fig. 4). These 
features are typical of the targeting signals found on other 
proteins imported into mitochondria [18]. This fact and the 
overall evel of homology of the P43 protein sequence to that 
of E. coli EF-Tu and yeast mEF-Tu strongly suggests that P43 
is a human mitochondrial e ongation factor. This hypothesis 
supported by the finding that the functionally important amino 
acids of EF-Tu, as revealed in a recent study of the crystal 
structure [19], are conserved in P43 (Fig. 4). 
EFTu becomes activated when it exchanges GDP for GTP 
resulting in a conformational change in the protein and the 
formation of a cleft between two domains of the protein which 
has been proposed as the binding site for amino acyl-tRNA 
[19]. The alignment of the amino acid sequences of P43 with 
bacterial and mitochondrial elongation factors shows that the 
amino acids which bind GTP and also undergo a conforma- 
tional change in response to GTP binding are spatially con- 
served within these proteins (functionally conserved sequences 
boxed in Fig. 4). Once the ternary complex of EF-Tu, GTP and 
the aminoacyl-tRNA are bound to the A site of the ribosome, 
GTP hydrolysis occurs leading to release of the EF-Tu GDP 
from the protein synthesis machinery. It is thought hat binding 
of EFTu to the ribosome triggers hydrolysis of GTP thereby 
promoting the release of EFTu-GDP from the ribosome so that 
it can participate inanother exchange reaction. All of the amino 
acids implicated in the intrinsic and effector mediated mecha- 
nism of GTP hydrolysis are also conserved in P43 (see Fig. 4 
and legend). 
As the activity of some elongation factors is regulated by 
phosphorylation and dephosphorylation we scanned the P43 
amino acid sequence for potential consensus phosphorylation 
sites using the Motifs program of the Genetics Computer 
Group Software package. This analysis revealed two potential 
protein kinase C (PKC) phosphorylation sites at amino acid 
positions 345 and 423 and four putative caesin kinase II (CKII) 
phosphorylation sites at amino acid positions 304, 360, 423, and 
443. The PKC site at position 345 and the CKII phosphoryla- 
tion sites at amino acid positions 304 and 360 are spatially 
conserved within the yeast and E. coli EF-Tu protein sequences 
(Fig. 4). 
3.4. Mitochondr&l location of P43 
As the predicted amino acid sequence of P43 showed highest 
homology to elongation factors of mitochondrial nd bacterial 
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-91 GGCACGAGCCGGAAGT -76 
-75 GCCTTCCAGCCGCACGCCCTTCCTCTTCTGTGAGCTCGGGCTCCTGGTCCCAAGTGGGGAATTACCGGCGCGAGT -I 
1 ATGACCACAATGGCGGCCGCCACCCTGCTGCGCGCGACGCCCCACTTCAGCGGTCTCGCCGCCGGCCGGACCTTC 75 
1 MetThrThrMetAlaAlaAlaThrLeuLeuArgAlaThrProHisPheSerGlyLeuAlaAlaGlyArgThrPhe 25 
76 CTGCTGCAGGGTCTGTTGCGGCTGCTGAAAGCCCCGGCATTGCCTCTCTTGTGCCGCGGCCTGGCCGTGGAGGCC 150 
26 LeuLeuGlnGlyLeuLeuArgLeuLeuLysAlaProAlaLeuProLeuLeuCysArgGlyLeuAlaValGluAla 50 
151 AAGAAGACTTACGTGCGCGACAAGCCACATGTGAATGTGGGTACCATTGGCCATGTGGACCACGGGAAGACCACG 225 
51 LysLysThrTyrValArgAsnLvsProHisVa]AsnValGlvThrIleGlyHisValAspHisGlyLysThrThr 75 
peptide A 
226 CTGACTGCAGCCATCACGAAGATTCTAGCTGAGGGAGGTGGGGCTAAGTTCAAGAAGTACGAGGAGATTGACAAT 300 
76 LeuThrAlaAlaI leThrLysI leLeuAlaGluGlyGlyGlyAlaLysPheLysLysTyrGluGluI leAspAsn i00 
301 GCCCCGGAGGAGCGAGCTC~TATCACCATCAATGCGGCTCATGTGGAGTATAGCACTGCCGCCCGCCACTAC 375 
i01 AlaProGluGluArgAlaArgGlyI leThrI leAsnAlaAlaHisValGluTyrSerThrAlaAlaArgHisTyr 125 
376 GCCCACACAGACTGCCCGGGTCATGCAGATTATGTTAAGAATATGATCACAGGCACTGCACCCCTCGACGGCTGC 450 
126 AlaHisThrAspCysProGlyHisAlaAspTyrValLysAsn~9_~IleThrGlyThrAlaProLeuAspGlyCys 150 
451 ATCCTGGTGGTAGCAGCCAATGACGGCCCCATGCCCCAGACCCGAGAGCACTTATTACTGGCCAGACAGATTGGG 525 
151 I leLeuValValAlaAlaAsnAspGlyProMetProGlnThrArgGluHisLeuLeuLeuAlaArgGlnI leGly 175 
526 GTC-GAGCATGTGGTGGTGTATGTGAACAAGGCTGACGCTGTCCAGGACTCTGAGATGGTGGAACTGGAGATCCGG 600 
176 ValGluHisValValValTyrValAsnLysAlaAspAlaValGlnAspSerGluMetValGluLeuGluI leArg 200 
601 GAGCTGCTCACCGAGTTTGGCTATAAAGGGGAGGAGACCCCAGTCATCGTAGGCTCTGCTCTCTGTGCCCTTGAG 675 
201 GluLeuLeuThrGluPheGlyTyrLysGlyGluGluThrProValI leValGlySerAlaLeuCysAlaLeuGlu 225 
676 GGTCGGGACCCTGAGTTAGGCCTGAAGTCTGTGCAGAAGCTACTGGATGCTGTGGACACTTACATCCCAGTGCCC 750 
226 GlyArgAspProGluLeuGlyLeuLysSerValGlnLysLeuLeuAsDAlaValAsDThrTvrI leProVa]Pro 250 
peptide B 
751 GCCCGGGACCTGGAGAAGCCTTTCCTGCTGCCTGTGGAGGCGGTGTACTCCGTCCCTGGCCGTGGCACCGTGGTG 825 
251 ~]aAraAsDLeuGluLvsProPheLeuLeuProValGluAlaValTvrSerValProGlvArgGlyThrValVal 275 
826 ACAGGTACACTAGAGCGTGGCATTTTAAAGAAGGGAGACGAGTGTGAGCTCCTAGGACATAGCAAGAACATCCGC 900 
276 ThrGlyThrLeuGluArgGlyI leLeuLysLysGlyAspGluCysGluLeuLeuGlyHisSerLysAsnI leArg 300 
901 ACTGTGGTGACAGGCATTGAGATGTTCCACAAGAGCCTGGAGAGGGCCGAGGCCGGAGATAACCTCGGGGCCCTG 975 
301 ThrValValThrGlyI leGluMetPheHisLysSerLeuGluArgAlaGluAlaGlyAspAsnLeuGlyAlaLeu 325 
976 GTCCGAGGCTTGAAGCGGGAGGACTTGCGGCGGGGCCTGGTCATGGTCAAGCCAGGTTCCATCAAGCCCCACCAG 1050 
326 ValArgGlyLeuLysArgGluAspLeuArgArgGlyLeuValMetValLysProGlySerI leLysProHisGln 350 
1051 AAGGTGGAGGCCCAGGTTTACATCCTCAGCAAGGAGGAAGGTGGCCGCCACAAGCCCTTTGTGTCCCACTTCATG 1125 
326 LysValGluAlaGlnValTvrI leLeuSerLvsGluGluGlyGlyArgHisLysProPheValSerHisPheMet 375 
peptide C 
1126 CCTGTCATGTTCTCCCTGACTTGGGACATGGCCTGTCGGATTATCCTGCCCCCAGAGAAGGAGCTTGCCATGCCC 1200 
376 ProValMetPheSerLeuThrTrpAspMetAlaCysArgI leI leLeuProProGluLysGluLeuAlaMetPro 400 
1201 GGGGAGGACCTGAAGTTCAACCTAATCTTGCGGCAGCCAATGATCTTAGAGAAAGGCCAGCGTTTCACCCTGCGA 1275 
401 GlyGluAspLeuLysPheAsnLeuI leLeuArgGlnProMetI leLeuGluLysGlyGlnArgPheThrLeuArg 425 
1276 GATGGCAACCGGACTATTGGCACCGGTCTAGTCACCAACACGCTGGCCATGACTGAGGAGGAGAAGAATATCAAA 1350 
426 AspGlyAsnArgThrI leGlyThrGlyLeuValThrAsnThrLeuAlaMetThrGluGluGluLysAsnI leLys 452 
1351 TGGGGTTGAGTGTGCAGATCTCTGCTCAGCTTTCCTTGCGTTTAAGGCCTGCCCTAGCCAGGGCTCCCTCCTGCT 1425 
451 TrpGly 452 
1426 TCCAGTACCCTCTCATGGCATAGGCTGCAACCCAGCAGAGGGCAGCTAGATGGACATTTCCCCTGCTCGGAAGGG 1500 
1501 TTGGCCTGCCTGGCTGGGGAGGTCAGTAAACTTTGAATAGTAAGCCAAAAAAA 1553 
Fig. 3. Nucleotide sequence and predicted amino acid sequence of the P43 gene product. The first four methionine residues are underlined and the 
predicted amino acid sequence of P43 is numbered from first of the two possible ATG translation initiation codons. The coding sequence of 1356 
nucleotides would encode for a protein of 452 amino acids with a predicted molecular weight of approximately 49.5 kDa. The three tryptic peptides 
of P43 which had been sequenced are underlined. The N terminal sequences derived from the overlapping cDNA clone pBS43.7 start at position 
-91 and end at position +15. 
origin we investigated whether P43 was mitochondrially located 
by cellular fractionation and immunoblotting. The results of 
immunoblotting with proteins recovered at different stages dur- 
ing the isolation of mitochondria from intact HeLa cells is 
shown in Fig. 113. As expected P43 was detected in the pellet 
of unlysed cells and nuclei that were recovered after gentle lysis 
by Dounce homogenisation. P43 could be completely recovered 
from the low speed supernatant by centrifugation at 10,000 × g 
for 20 min indicating that the antigen is most probably associ- 
ated with the pellet of mitochondria. The distribution of Hsp 
60, a protein associated with the inner and outer membrane of 
mitochondria, among the cellular fractions of HeLa cells was 
similar to P43, providing further evidence for the mitochondrial 
localisation of P43 (Fig. 1C). 
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* . . . .  * * * .  * . *  ***# . . . .  * . . . . . . .  
P43 MTTMAAATLLRATPHFSGLAAGRTFLLQGLLRLLKAPALPLLCRGLAVEAKK- - -TY  54 
mEF-Tu  yeast  MSALLPRLLTRTA- -FK- -ASGK . . . . . .  LLRLS  . . . . .  SV ISRTFSQTTTSYA~AF 42 
EF -Tu  E. co l i  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  SKEKF  5 
000  0 " °" 
VRDKPHVNVGTIGHVDHGKTTLTAAITK ILAEGGGAKFKKYEE IDNAPEERARGIT INAAHVEYSTAARHY~4TD 129 
DRSKPHVNZGTIGHVDHGKTTLTAAITKTLAAKGGANFLDYAAIDKAPEERARGIT ISTAHVEYETAKRHYSHVD 117 
ERTKPHVNVGTIGHVDHGKTTLTAAITTVLAKTYGGAARAFDQIDNAPEEKARG!T INTSHVEYDTPTRHYAHVD 80 
. . . .  i BoxA BoxB 
CP  GHADYVKNMITGTA PLDGCILWAANDGPMPQTREHLLLARQIGVEHVVVYVINKADIAVQDSEMVEL-~-  197 
CP  GHADYZKNMITGAA QMDGAI IWAATDGQMPQTREHLLLARQVGVQHIWFV INKVDIT IDDPEMLELVEM 188 
CP[ GHADYVKN-MITGAA[  QMDGAILWAATDGPMPQTREHILLGRQVGVPY I IVFL  INKCD I MVDDEELLELVEM 151 
**  ***** . *******  . . * *  **************************  . . . .  * . .  * *  * . *  * . . * *  
BoxC 
E IRELLTEFGYKGEETPVIVG[~' ]CALEGRDPELGLKSVQKLLDAVDTY IPVPARDLEKPFLLPVF~VYSVPG 270 
EMRELLNEYGFDGDNAPI IMGISAL ICALEGRQPEIGEQAIMKLLDAVDEYIPTPERDLNKPFLMPVEDIFS ISG 261  
EVRELLSQYDFPGDDTP IVRG]SAL~KALEG-DAEW-EAKILELAGFLDSY IPEPERAIDKPFLLP IEDVFS ISG 222  
****  * * * ***  ****  * * * ***  * * ****  * * * * 
cKrz $ i $ 
RGTVVTGTLERGILKKGDECELLGHSKN- IRTVVTGIEMFHKSLERAEAGDNLGALVRGLKREDLRRGLVMVKPG 344 
RGTWTGRVERGNLKKGEELE IVGHNSTPLKTTVTGIEMFRKELDSAMAGDNAGVLLRGIRRDQLKRGMVLAKPG 336 
RGTVVTGRVERG I I KVGEEVE IVGI  KETQ - KSTC TGVEMFRKLLDEGRAGENVGVLLRG ! KREE I ERGQVLAKPG 296 
PKC CK I I  
S IKPHQKVEAQVYILSKEEGGRHKPFVSHFMPVMFSLTWDMACRI ILPPEKE . . . .  LAMPGEDLKFNL ILRQPMI  415  
TVKAHTKILASLY ILSKEEGGRHSGFGENYRPQMFIRTADVTVVMRFPKEVEDHSMQVMPGDNVEMECDLIHPTP  411  
T IKPHTKFESEVY ILSKDEGGRHTPFFKGYRPQFYFRTTDVTGTIELPEGVE . . . .  MVMPGDNIKMVVTL IHP IA  367 
. . . * ****  *****  . * . . * * ***  * . 
LEKGQRFTLRDGNRT I GTGLVTNTLAMTEEEKNI  KWG 452 
LEVGQRFNI  REGGRTVGTGL ITR I  I E . . . . . . . . . . .  437  
MDDGLRFAI  REGGRTVGAGWAKVLS . . . . . . . . . . .  393  
• . * * * . . * . * . ** . * . *  . . . . . . .  
Fig. 4. Comparison of amino acid sequences in P43, the ,£ cerevisae mitochondrial e ongation factor (mEF-Tu) and the EF-Tu of E. coil. The 
alignment was optimised by computer analysis• *, identical amino acids in all three proteins; ",amino acids with similar biochemical properties. Box 
A: sequences which mediate the conformational change in response to nucleotide exchange. Boxes B and C: conserved sequences involved in guanine 
ring binding• o, amino acids involved in nucleotide binding; o, amino acids involved in GTPase mechanism; $, charged residues which may be involved 
in binding of the amino acyl-tRNA. For the N-terminal signal sequences only amino acid residues with a positive charge are indicated by +. Potential 
phosphorylation sites for PCK and CKII which are conserved inall three proteins are underlined. 
3.5. Southern and Northern blot analysis 
A Southern blot of HindlII digested DNAs from three differ- 
ent hepatoma cell lines was hybridised with a 32p-labelled KpnI 
fragment of the p43 cDNA. Two DNA fragments of approxi- 
mately 18 kb and 4.0 kb in size were detected in each track 
(Fig. 5A). 
A Northern blot of mRNA from the hepatoma cell line 
PLC/PRF/5, a normal liver cell line CCL13 and the HeLa 
tumour cell line was hybridised with the same probe as that 
used for Southern blot hybridization. Fig. 5b shows that a 
single transcript of approximately 2.2 kb in size was detected 
in all three cell lines. Based on the length of the cDNA and the 
predicted start site for the P43 ORF, the mRNA transcript 
would therefore contain approximately 650 nt of 5' non-coding 
sequence. The results show that the steady state levels of 
mRNAp43 were approximately the same in both tumour (HeLa 
and PLC/PRF/5) and normal (CCL13) cells lines. This was not 
due to differences in the amounts of mRNA loaded as approx- 
imately the same levels of a fl-actin control transcript were 
detected in each cell line (not shown). However, these tumour 
cell lines have previously been shown to express ubstantially 
higher amounts of P43 antigen than the normal iver cell line 
by Western blotting [1]. The reasons for the differences in 
mRNA and protein levels are not known but warrant further 
investigation as they may indicate differences in the protein 
stability. 
3.6. Chromosomal mapping of the p43 gene by in situ 
hybridization 
Metaphase spreads of chromosomes from a normal male 
lymphoblastoid cell line were hybridised to a biotinylated probe 
prepared from pBS43.5 and detected by fluorescence in-situ 
hybridization using avidin FITC. A signal was reproducibly 
detected on chromosome 16 between pl l .2 and 12 and also 
near the centromere on the long arm of chromosome 17 indicat- 
ing that similar sequences must be present at two loci (Fig. 6). 
While a signal was detected on both chromatids of metaphase 
chromosome 16 this was not the case for chromosome 17. 
However, this might be due to the constriction of the chromo- 
some at the centromeric region. 
4. Discussion 
The cDNA for p43 was isolated by the screening of a human 
liver cDNA library with oligonucleotide probes based on the 
sequences of tryptic peptides of affinity purified P43. Analysis 
of the nucleotide sequences of two overlapping clones revealed 
one long ORF of 1356 bp, a 197 bp 3'-untranslated region plus 
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Fig. 5. Southern and Northern hybridisation analysis. (A) Southern 
blot of HindIII digested genomic DNA from three cultured hepatoma 
cell lines as follows; lane 1, primary hepatoma CB8017; lane 2, Huh7; 
lane 3, PLC/PRF/5 (Alexander cells). (B) Northern blot analysis of 
poly(A) ÷ RNA isolated from cultured cell lines as follows; lane 1, 
PLC/PRF/5 (Alexander cells); lane 2, normal liver line CCL13; lane 3, 
HeLa. Hybridisation to a control probe (fl actin) showed that approx- 
imately equal amounts of mRNA were loaded in each track (not 
shown). 
poly(A) ÷ tail and a 5'-untranslated region. This is compatible 
with the size of the mRNA transcript (2.2 kb) detected in 
Northern blots. Evidence that the cDNA we have isolated en- 
codes the antigen detected by the MAb68 is provided by the fact 
that the peptide sequences derived from the antibody affinity 
purified protein are encoded within the ORF predicted for P43. 
The product of the cDNA when produced in E. coli as a fusion 
protein to lacZ specifically reacts with MAb68. Additionally, 
we have shown by immunoblotting that an increased level of 
P43 is detected in liver cells transfected with a plasmid express- 
ing the cDNA we have isolated and characterised. 
Fluorescence in situ hybridisation with the cDNA encoding 
P43 was used to localize the gene to chromosome 16 between 
pl 1.2 and 12 and also to a position ear the centromere on the 
long arm of chromosome 17. Future studies are aimed at estab- 
lishing whether both loci encode proteins with similar proper- 
ties and functions or whether a pseudogene is located at one 
of the loci. 
The deduced amino acid sequence of P43 is remarkably sim- 
ilar to that of E. coli EF-Tu and the mitochondrial EF-Tu of 
S. eerevisiae. Furthermore, we have shown that the amino acid 
sequences proposed to be important for nucleotide binding and 
the mechanisms of intrinsic and effector-enhanced GTPase ac- 
tivity of EF-Tu from Thermus thermophilus are completely con- 
served in P43. Several potential sites for phosphorylation by
PCK and CKII were found in P43, some which were also 
conserved in the yeast mEF-Tu and the EF-Tu of E. coli. As 
these sites occur commonly in proteins and are not necessarily 
phosphorylated their significance would need to be further in- 
vestigated, istributed. 
The N-terminal sequences of P43 share features in common 
with the N-terminal sequences of S. cerevisiae mEF-Tu and 
other nuclear-encoded mitochondrial proteins which become 
processed uring transport into the mitochondria. The process- 
ing of P43 in this way would account for the discrepancy be- 
tween the predicted molecular weight of 49.5 kDa and the 43 
kDa sized protein detected on Western blots. A protein corre- 
sponding to the predicted size of the unprocessed precursor is 
faintly detected in Western blots of protein extracts from cells 
transfected with a cDNA expression plasmid (Fig. 2). This may 
have arisen as a consequence of the over-expression f P43 in 
transfected cells leading to incomplete processing of the mito- 
chondrial targeting signal. Further evidence for the mitochon- 
drial localisation of P43 comes from the finding that the mito- 
chondria associated proteins Hsp 60 and P43 are similarly 
distributed among the subcellular f actions of HeLa cells. 
Previous tudies howed that the expression of P43 was only 
readily detected in tumour cell lines and not normal liver tissues 
or cell lines by immunoblotting [1]. However, in contrast o 
these previous results we have found that P43 is in fact ex- 
pressed in normal tissues but at markedly different levels. This 
may be due to the fact that the enhanced chemiluminescence 
detection system used here is more sensitive and highlights a
need to re-examine the levels of P43 in normal and transformed 
cells of different issue origin. 
The finding that P43 is most likely a human mitochondrial 
elongation factor and that its expression is elevated in trans- 
formed cells led us to investigate the possible tissue specific 
differences in the levels of expression of P43. Relatively high 
levels of P43 were detected in mouse heart, brain, liver, and 
kidney whereas expression was substantially lower in the 
spleen, skeletal muscle, lung and pancreas. The relatively high 
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Fig. 6. (A) Fluorescence in situ hybridisation fP43 probe to metaphase 
chromosomes prepared from a normal male lymphoblastoid cell line. 
Localisation to chromosome 16 and 17 is indicated. (B) Frequency 
distribution of hybridisation signals detected on chromosomes 16 
and 17. 
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level of P43 expression in the heart, brain and kidney would 
correlate with its potential role as a mitochondrial e ongation 
factor as these tissues have intrinsically high levels of oxidative 
metabolism. Interestingly, a related protein with higher molec- 
ular weight (approximately 50kDa) was abundantly expressed 
in the lung and in amounts which were higher than those ob- 
served with other tissues. Although this protein might simply 
be a tissue specific protein which cross-reacts with the antibody 
it warrants further investigation asit might be a related protein 
with a different function or a modified form of P43 found only 
in the lung. In this respect it is interesting to note that eukar- 
yotic protein elongation factors are increasingly being shown 
to be involved in functions other than protein synthesis, uch 
as organisation of the mitotic apparatus [20], developmental 
regulation [21,22], aging [23], signal transduction [24] and trans- 
formation [25]. 
The increased expression of the human cytoplasmic elonga- 
tion factor EF-la in adenocarcinomas has also been recently 
reported [26]. Moreover constitutive expression of EF-la in- 
creases the susceptibility of several fibroblast cell lines to trans- 
formation [25]. The expression of other eukaryotic proteins 
involved in protein translation such as eIF-4E and eIF-2a has 
also been shown to increase in response to growth induction 
by the cellular oncogene c-myc [27]. An increase in steady state 
levels of mitochondrial transcripts and nuclear genes encoding 
mitochondrial proteins is also found in hepatoma cells [28]. 
Taken together the results uggest that components of the pro- 
tein translation machinery may play an important role in the 
regulation of cell growth. 
Mitochondria re thought o have arose by the invasion of 
aerobic or anaerobic photosynthetic bacteria into ancestral 
protokaryotic cells [29] and several components of the mito- 
chondrial translation machinery, characterised so far in yeast, 
share similarities with their prokaryotic ounterparts. Despite 
these similarities previous attempts to clone mammalian mito- 
chondrial translation i itiation and elongation factors by ap- 
proaches based on their expected homology have been unsuc- 
cessful. The only mitochondrial e ongation factor to be cloned 
previously (the rat mtEF-G) was identified because of its fortu- 
itous homology to a domain of the growth hormone receptor 
[30]. The cloning of the first human mitochondrial e ongation 
factor should prove useful for investigating protein synthesis n 
normal mammalian mitochondria aswell as its role in diseases 
attributed to mitochondrial dysfunction. We are currently at- 
tempting to investigate the possible effects of increased P43 
expression on cell growth, mitochondrial physiology, and 
transformation. 
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